Plazomicin Study in ESRD Patients Receiving IHD

Summary

This study is being conducted to directly characterize the pharmacokinetic (PK) profile of plazomicin following administration of a single oral dose before and after IHD in subjects with ESRD. This PK assessment will be used to provide appropriate plazomicin dosing recommendations for patients with ESRD receiving IHD.

Timeline

Start

2021-01-05

Primary completion

2021-03-08

Completion

2021-06-09

Drugs

Indications